Bone-marrow-derived cell transfer after ST-elevation myocardial infarction: lessons from the BOOST trial

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Stem Cell Therapy

Background:

• Bone marrow-derived stem and progenitor cells show potential for cardiac repair.
• Acute myocardial infarction (AMI) leads to significant cardiac dysfunction.

Purpose of the Study:

• To evaluate the efficacy and safety of intracoronary autologous bone marrow cells (BMCs) in patients with acute ST-elevation myocardial infarction (STEMI).
• To assess the impact of BMC transfer on left ventricular function and clinical outcomes.

Main Methods:

• The randomized, controlled BOOST trial enrolled patients post-percutaneous coronary intervention for STEMI.
• Patients received intracoronary autologous BMCs or placebo.
• Cardiac function was assessed using magnetic resonance imaging at 6 and 18 months.

Main Results:

• BMC treatment significantly improved global left ventricular ejection fraction at 6 months compared to controls.
• Enhanced systolic function was observed in myocardial segments adjacent to the infarct area, with positive effects on diastolic function.
• No increase in adverse clinical events, in-stent re-stenosis, or proarrhythmic effects was noted. Sustained improvement in ejection fraction at 18 months.

Conclusions:

• Intracoronary autologous BMC transfer is a safe and promising approach to improve cardiac function after reperfused STEMI.
• Beneficial effects are achieved despite limited cardiac homing of BMCs.
• This therapy offers a novel strategy for post-myocardial infarction recovery.